Genetic screening and diagnosis

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 2, 2005, Pages 163-169

  Lau, Tze Kin ^a   Leung, Tse Ngong ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Fetal DNA; Genetic screening and diagnosis; Prenatal diagnosis

Indexed keywords

DNA; FETAL DNA; UNCLASSIFIED DRUG;

CHRONIC DISEASE; DISEASE PREDISPOSITION; DNA MICROARRAY; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN GENOME PROJECT; MASS SCREENING; MEDICAL ETHICS; MEDICOLEGAL ASPECT; MOLECULAR BIOLOGY; NON INVASIVE MEASUREMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW;

EID: 15944426763     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000162187.99219.e0     Document Type: Review

References (49)

1. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191:45-67. An excellent and comprehensive review of first trimester screening of chromosomal abnormalities, including the theoretical basis, mathematical modelling, efficacy, clinical implementation, training and auditing. Comparisons with other screening tests are also reported.
2. Ball RH. Invasive fetal testing. Curr Opin Obstet Gynecol 2004; 16:159-162. A review and comparison of currently available invasive fetal diagnostic tests.
3. Watson J, Crick FHC. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953; 71:737-738.
4. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431:931-945. This is the latest report from the Human Genome Project, reporting the latest findings in the finishing stage of the project.
5. Shaffer LG, Bejjani BA. A cytogeneticist's perspective on genomic microarrays. Hum Reprod Update 2004; 10:221-226. An excellent review of the latest development in molecular cytogenetics and its implications for clinical practice as well as research.
6. Galvin P, Clarke LA, Harvey S, et al. Microarray analysis in cystic fibrosis. J Cyst Fibros 2004; 3(Suppl 2):29-33. Excellent discussion on the use of microarray technology for the screening and diagnosis of cystic fibrosis. This is an example of the application of microarray technology in genetic screening.
7. Collins FS, Green ED, Guttmacher AE, et al. US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003; 422:835-847. An interesting article which summarizes the predictions of experts as to what lies ahead in genomic research, and its consequences.
8. Anonymous. Phenylketonuria (PKU): screening and management. NIH Consens Statement 2000; 17:1-33.
9. Bach G, Tomczak J, Risch N, et al. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am J Med Genet 2001; 99:70-75.
10. Saxena A. Issues in newborn screening. Genet Test 2003; 7:131-134. A concise review of the latest development and advances in neonatal screening, as well as problems that arise from the new technology.
11. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5:669-676. An excellent review of the relationship between genetics and pharmacology. This highlighted the potential argument for genetic screening and diagnosis for genetic traits of pharmacological importance.
12. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature. Int J Cancer 2004; 112:357-364. The discovery of an association between BRCA mutations and breast cancer has led to a strong argument for genetic screening of these mutations. This article reviewed the current literature on whether screening could result in effective prevention of breast cancer.
13. Chaer RA, Billeh R, Massad MG. Genetics and gene manipulation therapy of premature coronary artery disease. Cardiology 2004; 101:122-130. A general review on how to identify the genetic basis of coronary artery disease, and how to use the genetic information to prevent this deadly disease.
14. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet 2004; 363:1633-1641. A very readable overview of preimplantation genetic diagnosis, from history, biopsy technique, molecular tests used, indications and outcomes, to future development.
15. ESHRE PGD Consortium Steering Committee. ESHRE Preimplantation Genetic Diagnosis Consortium: data collection III (May 2001). Hum Reprod 2002; 17:233-246.
16. Jurkovic D, Jauniaux E, Campbell S, et al. Coelocentesis: a new technique for early prenatal diagnosis. Lancet 1993; 341:1623-1624,
17. Cruger DG, Bruun-Petersen G, Kolvraa S. Early prenatal diagnosis: standard cytogenetic analysis of coelomic cells obtained by coelocentesis. Prenat Diagn 1996; 16:945-949.
18. Lau TK, Fung TY, Wong YF, et al. A study of fetal sex determination in coelomic fluid. Gynecol Obstet Invest 1998; 45:16-18.
19. Makrydimas G, Georgiou I, Kranas V, et al. Prenatal diagnosis of beta-thalassaemia by coelocentesis. Mol Hum Reprod 1997; 3:729-731.
20. Makrydimas G, Georgiou I, Bouba I, et al. Early prenatal diagnosis by celocentesis. Ultrasound Obstet Gynecol 2004; 23:482-485. This is the largest case series of prenatal diagnosis using celocentesis.
21. Makrydimas G, Kaponis A, Skentou C, et al. Short-term safety of celocentesis for the mother and the fetus. Ultrasound Obstet Gynecol 2002; 19:243-245.
22. Bianchi DW, Williams JM, Sullivan LM, et al. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am J Hum Genet 1997; 61:822-829.
23. Ariga H, Ohto H, Busch MP, et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for non-invasive prenatal diagnosis. Transfusion 2001; 41:1524-1530.
24. Bianchi DW, Simpson JL, Jackson LG, et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat Diagn 2002; 22:609-615.
25. Jackson L. Fetal cells and DNA in maternal blood. Prenat Diagn 2003; 23:837-846.
26. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350:485-487.
27. Lo YMD, Tein MSC, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62:768-775.
28. Rijnders RJ, Van Der Luijt RB, Peters ED, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003; 23:1042-1044. In a study of pregnant women after successful in-vitro fertilization, the authors found that fetal DNA is detected in maternal plasma as early as 5 weeks and 2 days.
29. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64:218-224.
30. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. N Engl J Med 2002; 346:1502.
31. Bartha JL, Finning K, Soothill PW. Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21-hydroxylase deficiency. Obstet Gynecol 2003; 101:1135-1136. Fetal sex was correctly predicted from maternal plasma at 6 weeks of gestation in a woman whose baby was at risk of 21-hydroxylase deficiency.
32. Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 2000; 356:1170.
33. Amicucci P, Gennarelli M, Novelli G, et al. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 2000; 46:301-302.
34. Chen CP, Chern SR, Wang W. Fetal DNA analyzed in plasma from a mother's three consecutive pregnancies to detect paternally inherited aneuploidy. Clin Chem 2001; 47:937-939.
35. Lo YMD, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-1738.
36. Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann NY Acad Sci 2004; 1022:119-123. Prenatal fetal Rh genotyping from cell-free DNA in maternal plasma is the first large-scale clinical application of non-invasive prenatal diagnosis. This reports the performance of a program which was started only 4 years after the first discovery of cell-free fetal DNA in maternal plasma.
37. van der Schoot CE, Tax GH, Rijnders RJ, de Haas M, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003; 17:31-44. A general review of prenatal Rh typing, and a cost analysis of using the latest Rh genotyping by fetal DNA in maternal plasma.
38. Chiu RW, Lau TK, Cheung PT, et al. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin Chem 2002; 48:778-780.
39. Chiu RW, Lau TK, Leung TN, et al. Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet 2002; 360:998-1000.
40. Ding C, Chiu RW, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci USA 2004; 101:10762-10767. An important study describing a novel method by which noninvasive prenatal diagnosis in a mother and father carrying identical beta-thalassemia mutations was accomplished.
41. Chan KC, Zhang J, Hui AB, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004; 50:88-92. One of the first studies showing that cell-free fetal DNA has characteristics that are different from those of maternal DNA. This opens up the possibility of purifying fetal DNA from the maternal circulation.
42. Poon LL, Leung TN, Lau TK, et al. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. Clin Chem 2002; 48:35-41.
43. Chiu RW, Poon LL, Lau TK, et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001; 47:1607-1613.
44. Ferns GA, O'Dowd D, Wark G, et al. Molecular diagnostics in routine practice: quality issues and application to complex disease. Ann Clin Biochem 2003; 40:309-312. This paper describes how genetic testing could be regulated.
45. Williams LO, Cole EC, Lubin IM, et al. Quality assurance in human molecular genetics testing: status and recommendations. Arch Pathol Lab Med 2003; 127:1353-1358. This is a detailed report on the combined effort of trying to elucidate the current problems in quality assurance in genetic testing laboratories, and the way forward.
46. Elias S. The human Gynome. Am J Obstet Gynecol 2004; 190:1528-1533. This review summarizes the genetic basis of common obstetrical and gynecological diseases.
47. Dennis C. Deaf by design. Nature 2004; 431:894-896. A story of an unusual request; some couples wish to make the active choice to have a baby with a specific disability. This is a good example of new technologies bringing in new problems to be solved.
48. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003; 349:996-998. This article concisely reports the latest impact, both positive and negative, of information generated by genomic research. It also provides a vision of the future of genomic research and applications.
49. Elias S, Annas GJ. Generic consent for genetic screening. N Engl J Med 1994; 330:1611-1613.